David Pickar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11347316/publications.pdf

Version: 2024-02-01

117 papers	8,410 citations	44069 48 h-index	46799 89 g-index
117 all docs	117 docs citations	117 times ranked	4567 citing authors

#	Article	IF	Citations
1	Responses to Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease. New England Journal of Medicine, 1986, 314, 1329-1335.	27.0	762
2	Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics. Neuropsychopharmacology, 1997, 17, 141-150.	5.4	603
3	Clinical and Biologic Response to Clozapine in Patients With Schizophrenia. Archives of General Psychiatry, 1992, 49, 345.	12.3	352
4	Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia. American Journal of Psychiatry, 1999, 156, 1646-1649.	7.2	313
5	Longitudinal Measurement of Plasma Homovanillic Acid Levels in Schizophrenic Patients. Archives of General Psychiatry, 1986, 43, 669.	12.3	310
6	The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia. British Journal of Psychiatry, 1993, 162, 43-48.	2.8	283
7	Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers. Biological Psychiatry, 1998, 43, 811-816.	1.3	278
8	Cognitive Substrates of Thought Disorder, I: The Semantic System. American Journal of Psychiatry, 1998, 155, 1671-1676.	7.2	276
9	Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 437-447.	4.3	237
10	Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine. Biological Psychiatry, 1997, 42, 664-668.	1.3	185
11	Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication. Journal of Cerebral Blood Flow and Metabolism, 1985, 5, 201-206.	4.3	175
12	Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. , 1998, 29, 142-147.		175
13	Surgical stress in humans is acompanied by an increase in plasma beta-endorphin immunoreactivity. Life Sciences, 1981, 29, 1249-1254.	4.3	132
14	Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1987, 40, 2031-2039.	4.3	132
15	Increased temporal lobe glucose use in chronic schizophrenic patients. Biological Psychiatry, 1989, 25, 835-851.	1.3	131
16	Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia. British Journal of Psychiatry, 1996, 168, 571-579.	2.8	128
17	Is the Mechanism of Prefrontal Hypofunction in Depression the Same as in Schizophrenia?. British Journal of Psychiatry, 1993, 162, 183-192.	2.8	119
18	Dopamine D₂Receptor Density and Personal Detachment in Healthy Subjects. American Journal of Psychiatry, 1998, 155, 1440-1442.	7.2	117

#	Article	IF	Citations
19	Cognitive Substrates of Thought Disorder, II: Specifying a Candidate Cognitive Mechanism. American Journal of Psychiatry, 1998, 155, 1677-1684.	7.2	116
20	Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Research, 1985, 15, 281-292.	3.3	112
21	Short-term Naloxone Administration in Schizophrenic and Manic Patients. Archives of General Psychiatry, 1982, 39, 313.	12.3	100
22	Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Research, 1980, 3, 93-105.	3.3	91
23	Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis. Archives of General Psychiatry, 1990, 47, 641.	12.3	89
24	Naloxone effects on ?-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology, 1981, 74, 125-128.	3.1	87
25	Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology, 1985, 86, 432-437.	3.1	83
26	Symptoms and EEG Findings in the Borderline Syndrome. International Journal of Psychiatry in Medicine, 1986, 15, 201-211.	1.8	83
27	Clozapine response and the 5HT2C Cys23Ser polymorphism. NeuroReport, 1996, 7, 2100-2102.	1.2	78
28	BEHAVIOURAL EFFECTS AFTER HIGH DOSE NALOXONE ADMINISTRATION TO NORMAL VOLUNTEERS. Lancet, The, 1981, 318, 1110.	13.7	73
29	Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine. Biological Psychiatry, 1993, 34, 3-12.	1.3	72
30	Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia. American Journal of Psychiatry, 1998, 155, 979-981.	7.2	72
31	Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. European Archives of Psychiatry and Clinical Neuroscience, 1993, 243, 7-10.	3.2	71
32	Chronic corticosterone administration in rats: Behavioral and biochemical evidence of increased central dopaminergic activity. European Journal of Pharmacology, 1986, 122, 329-338.	3.5	69
33	CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine, 1985, 15, 335-340.	4.5	68
34	Pharmacogenomics of psychiatric disorders. Trends in Pharmacological Sciences, 2001, 22, 75-83.	8.7	68
35	Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage. Psychiatry Research, 1982, 6, 7-12.	3.3	66
36	Spectrum of EEG abnormalities during clozapine treatment. Electroencephalography and Clinical Neurophysiology, 1994, 91, 205-211.	0.3	66

#	Article	IF	Citations
37	Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research, 1988, 25, 187-194.	3.3	65
38	Increased serum soluble interleukin-2 receptors in caucasian and Korean schizophrenic patients. Biological Psychiatry, 1994, 35, 767-771.	1.3	61
39	Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. Life Sciences, 1981, 28, 931-935.	4.3	60
40	Physiological effects of high dose naloxone administration to normal adults. Life Sciences, 1982, 30, 2025-2031.	4.3	59
41	Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients. Archives of General Psychiatry, 1987, 44, 113.	12.3	57
42	Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 1994, 13, 133-143.	2.0	57
43	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology, 1999, 20, 29-34.	5.4	56
44	Maladaptive anticipatory saccades in schizophrenia. Biological Psychiatry, 1991, 30, 779-794.	1.3	55
45	CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophrenia Research, 1997, 25, 123-129.	2.0	53
46	Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping. Psychiatry Research, 1984, 12, 227-233.	3.3	50
47	Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychological Medicine, 1986, 16, 541-546.	4.5	50
48	High-dose naloxone affects task performance in normal subjects. Psychiatry Research, 1983, 8, 127-136.	3.3	49
49	Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophrenia Research, 1994, 12, 107-120.	2.0	49
50	The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1988, 43, 1141-1150.	4.3	48
51	Naloxone Reduces Food Intake in Humans. Psychosomatic Medicine, 1985, 47, 132-138.	2.0	47
52	Cerebrospinal fluid corticotropin-releasing hormone in depression: Relationship to noradrenergic function. Psychiatry Research, 1987, 20, 229-237.	3.3	47
53	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 4-7.	3.1	44
54	Life events in depression Relationship to subtypes. Journal of Affective Disorders, 1985, 9, 143-148.	4.1	44

#	Article	IF	Citations
55	Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Research, 1985, 16, 101-109.	3.3	43
56	Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatry Research, 1987, 21, 161-168.	3.3	40
57	The Role of the Endogenous Opioid System in the Human Stress Response. Psychiatric Clinics of North America, 1983, 6, 457-471.	1.3	39
58	PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS. Lancet, The, 1980, 315, 937.	13.7	38
59	Effects of Fentanyl on the Response of Plasma Beta-Endorphin Immunoreactivity to Surgery. Anesthesiology, 1982, 57, 468-472.	2.5	38
60	Adverse Effects of Antipsychotic Drugs. Drug Safety, 1993, 9, 429-436.	3.2	38
61	Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia. Neuropsychopharmacology, 1998, 19, 36-47.	5.4	38
62	Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research, 1996, 22, 215-222.	2.0	35
63	Selective and Nonselective Monoamine Oxidase Inhibitors. Archives of General Psychiatry, 1982, 39, 535.	12.3	34
64	Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. Journal of Affective Disorders, 1986, 10, 95-99.	4.1	34
65	Neurobiologic Correlates. Annals of the New York Academy of Sciences, 1986, 487, 189-196.	3.8	33
66	Idazoxan, an ??2 Antagonist, Augments Fluphenazine in. Journal of Clinical Psychopharmacology, 1993, 13, 264???267.	1.4	31
67	Apolipoprotein E Îµ4 and clinical phenotype in schizophrenia. Lancet, The, 1997, 350, 930-931.	13.7	31
68	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 8-12.	3.1	30
69	Cerebral structure in borderline personality disorder. Psychiatry Research, 1989, 27, 111-115.	3.3	30
70	Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients. Neuropsychopharmacology, 1993, 9, 111-115.	5.4	30
71	Dextroamphetamine infusions in normals result in correlated increases of plasma Î²-endorphin and cortisol immunoreactivity. Life Sciences, 1981, 29, 1243-1247.	4.3	29
72	Suicidal behavior in depression: Relationship to noradrenergic function. Biological Psychiatry, 1989, 25, 341-350.	1.3	29

#	Article	IF	Citations
73	Biologic tests in depression. Psychosomatics, 1984, 25, 443-451.	2.5	28
74	Single-dose naloxone acutely reduces eating in obese humans: Behavioral and biochemical effects. Biological Psychiatry, 1988, 24, 483-487.	1.3	28
75	Prednisone decreases CSF somatostatin in healthy humans: Implications for neuropsychiatric illness. Life Sciences, 1987, 41, 1929-1933.	4.3	27
76	Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients. Annals of the New York Academy of Sciences, 1988, 537, 339-346.	3.8	27
77	Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology, 1993, 112, S76-S84.	3.1	27
78	Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA. Biological Psychiatry, 1989, 25, 431-439.	1.3	25
79	Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. Neuropsychopharmacology, 2002, 27, 293-300.	5.4	24
80	Hormonal effects of high dose naloxone in humans. Neuropeptides, 1985, 6, 373-380.	2.2	23
81	The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia Evidence of a Sex Effect. Neuropsychopharmacology, 1999, 21, 632-640.	5.4	23
82	The relationship of plasma cortisol and Î²-endorphin immunoreactivity to surgical stress and postoperative analgesic requirement. General Hospital Psychiatry, 1983, 5, 93-98.	2.4	22
83	The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Life Sciences, 1991, 48, 1411-1416.	4.3	22
84	High-dose naloxone administration in chronic schizophrenia. Biological Psychiatry, 1985, 20, 573-575.	1.3	21
85	Effect Size of Symptom Status in Withdrawal of Typical Antipsychotics and Subsequent Clozapine Treatment in Patients With Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2003, 160, 1133-1138.	7.2	20
86	Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Research, 1981, 5, 87-93.	3.3	19
87	ENDORPHINS IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS. Annals of the New York Academy of Sciences, 1982, 398, 399-412.	3.8	19
88			

#	Article	IF	Citations
91	The Apolipoprotein E Îµ4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia A Preliminary Report. Neuropsychopharmacology, 1998, 19, 445-448.	5.4	17
92	Effects of Atypical Antipsychotic Drug Treatment on Amphetamine-Induced Striatal Dopamine Release in Patients with Psychotic Disorders. Neuropsychopharmacology, 1999, 20, 340-345.	5.4	17
93	Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia. Modern Problems of Pharmacopsychiatry, 1990, 24, 124-151.	2.5	16
94	Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. Biological Psychiatry, 1986, 21, 366-373.	1.3	15
95	Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. European Journal of Pharmacology, 1982, 80, 155-160.	3.5	14
96	Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. Pharmacology Biochemistry and Behavior, 1985, 23, 921-925.	2.9	14
97	Drug trials and heterogeneity in schizophrenia: The mean is not the end. Biological Psychiatry, 1990, 28, 1021-1025.	1.3	13
98	Effect of carbamazepine on CSF opioid activity: Relationship to antidepressant response. Psychiatry Research, 1981, 5, 59-66.	3.3	12
99	Extreme Elevations in Plasma Norepinephrine Associated with Decreased ??-Adrenergic Responsivity in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 1983, 3, 39???41.	1.4	12
100	Lithium Potentiation of Imipramine in Treatment Resistant Depression. British Journal of Psychiatry, 1985, 147, 582-583.	2.8	11
101	Predicting Response to Clozapine. CNS Drugs, 1999, 11, 317-326.	5.9	11
102	Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia. Neuropsychopharmacology, 2002, 26, 295-300.	5.4	11
103	Pharmacogenomics of psychiatric drug treatment. Psychiatric Clinics of North America, 2003, 26, 303-321.	1.3	11
104	Pharmacological Challenges to the Endogenous Opioid System in Affective Illness. Journal of Clinical Psychopharmacology, 1981, 1, 223-231.	1.4	10
105	A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid. Brain Research Bulletin, 1988, 20, 567-571.	3.0	10
106	Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Research, 1982, 7, 171-178.	3.3	9
107	Urinary excretion of free tyramine and of norepinephrine and its metabolites in unipolar depressed patients. Biological Psychiatry, 1986, 21, 221-224.	1.3	9
108	Studies of the Endogenous Opioid System in the Human Stress Response. , 1986, , 35-45.		9

#	Article	IF	Citations
109	Measurement of Endorphins in CSF. Modern Problems of Pharmacopsychiatry, 1981, 17, 246-262.	2.5	8
110	Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Research, 1990, 33, 259-267.	3.3	7
111	CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM. Annals of the New York Academy of Sciences, 1982, 398, 424-432.	3.8	6
112	Pre-Menopausal and Post-Menopausal Depressed Women. Australian and New Zealand Journal of Psychiatry, 1986, 20, 464-469.	2.3	6
113	Biologic Predictors of Clozapine Response in Schizophrenia. Psychiatric Annals, 1996, 26, 390-394.	0.1	4
114	TRH-induced prolactin release in unipolar depressed patients and controls. Journal of Psychiatric Research, 1988, 22, 221-225.	3.1	3
115	Endorphins and Affective Illness. , 1982, , 375-397.		3
116	Alprazolam-neuroleptic treatment in schizophrenia. Schizophrenia Research, 1989, 2, 215.	2.0	1
117	Challenges in patient management. European Psychiatry, 1998, 13, 219s-219s.	0.2	0